Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
- 16 February 2020
- Vol. 75 (5), 1043-1057
- https://doi.org/10.1111/all.14235
Abstract
Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) versus standard of care for patients with uncontrolled severe allergic asthma. Pubmed, EMBASE and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma‐related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualised asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50−0.81); dupilumab IRR 0.58 (95%CI 0.47−0.73); omalizumab IRR 0.56 (95%CI 0.42−0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty, however none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug‐related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6‐12 years old omalizumab decreased the annualised exacerbation rate [IRR 0.57 (95%CI 0.45‐0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 ‐1.83)], reduced ICS [mean difference (MD) ‐0.45 (95% CI ‐0.58 to ‐0.32)] and rescue medication use [ MD ‐0.41 (95%CI ‐0.66 to ‐0.15)].Keywords
Funding Information
- European Academy of Allergy and Clinical Immunology
This publication has 96 references indexed in Scilit:
- Burden of illness of patients with allergic asthma versus non-allergic asthmaJournal of Asthma, 2013
- A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic AsthmaJournal of Asthma, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenThe New England Journal of Medicine, 2011
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy ModelJournal of Allergy and Clinical Immunology, 2007
- Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical & Experimental Allergy, 2007
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003